Chad Hille, MD
Rheumatology · Baton Rouge, LANPI 1841677986
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Amgen at 31.2% of the total. 2025 is the largest year on record at $35,591, more than ten times the $114 reported in 2019.
Across 513 payments — averaging $100.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$16K
- Sanofi$16K
- Novartis$6K
- AbbVie$5K
- E.r. Squibb & Sons, L.L.C.$3K
- Johnson & Johnson$1K
- plus $4K from 20 others
Across 2 payments — averaging $234.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$469
What the payments were for
- Consulting fees$4,3008%
- Speaking & faculty fees$22,50644%
- Travel & lodging$2,6305%
- Food & beverage$21,93743%
- Education$2280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 115 | $16,100 |
| Sanofi | 43 | $15,944 |
| Novartis | 53 | $6,272 |
| AbbVie | 150 | $4,903 |
| E.r. Squibb & Sons, L.L.C. | 16 | $2,918 |
| Johnson & Johnson | 26 | $1,060 |
| UCB, Inc. | 28 | $784 |
| AstraZeneca(2 entities) | 17 | $754 |
| GSK | 11 | $578 |
| Mallinckrodt Hospital Products Inc. | 4 | $335 |
| Lilly USA, LLC | 7 | $289 |
| Dexcom, Inc. | 2 | $272 |
| Aurinia Pharma U.S., Inc. | 10 | $258 |
| Boehringer Ingelheim | 5 | $178 |
| Sobi, Inc | 3 | $154 |
| ANI Pharmaceuticals, Inc. | 5 | $129 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Gilead | 1 | $122 |
| Radius Health, Inc. | 5 | $111 |
| Janssen Scientific Affairs, LLC | 1 | $111 |
| Bioventus LLC | 1 | $50 |
| Organon | 4 | $42 |
| Genentech USA, Inc. | 2 | $41 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Pfizer | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,601 in reported general payments places this provider in the 85th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 73 | $478,286 |
| RinvoqUpadacitinib | 65 | $435,151 |
| Enbrel SureclickEtanercept | 41 | $306,164 |
| Orencia ClickjectAbatacept | 40 | $231,756 |
| KevzaraSarilumab | 28 | $123,748 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $121,359 |
| OtezlaApremilast | 23 | $105,037 |
| Humira(Cf)Adalimumab | 13 | $91,272 |
| Actemra ActpenTocilizumab | 16 | $70,947 |
| TymlosAbaloparatide | 16 | $41,156 |
| Hydroxychloroquine Sulfate | 301 | $10,179 |
| Colchicine | 84 | $3,324 |
| MethotrexateMethotrexate Sodium | 208 | $3,210 |
| Febuxostat | 33 | $2,539 |
| Mycophenolate Mofetil | 28 | $1,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $4,903 | $526,42478 claims |
| SanofiKevzara | $15,944 | $123,74828 claims |
| AmgenOtezla | $16,100 | $105,03723 claims |
| Radius Health, Inc.Tymlos | $111 | $41,15616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Baton Rouge
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Randall BeylBaton Rouge$112K
- Ronald CerutiBaton Rouge$29K
- Joseph NesheiwatBaton Rouge$18K
- Jen ErbilBaton Rouge$17K
- Hector MenaBaton Rouge$15K
- Stephen PolletBaton Rouge$14K
- Khanh HoBaton Rouge$12K
- Angele BourgBaton Rouge$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.